Vital

Peptides

MOTS-c Dosage: No Approved Dose, Evidence, and Vial Units

An honest answer on MOTS-c dosage: no approved human dose exists, what studies in people show so far, the FDA status, how to do the unit math for a 10 mg vial, and how to log a course.

Last reviewed

The Vital angle

Vital lets you attach a course to a saved peptide, with a start date, an end by a duration in weeks or a fixed date, a progress bar, a day-one reminder, and a warning before the end. Pausing a course stops its dose reminders without deleting the plan, and the peptide directory shows MOTS-c with its FDA status and a Limited Data evidence level.

MOTS-c dosage: the short answer

There is no approved or proven MOTS-c dosage for people. MOTS-c is not an FDA-approved drug for any use. On its compounding safety page, current as of April 22, 2026, the FDA says that it has not identified any human exposure data on drug products that contain MOTS-c. The MOTS-c "protocols" on seller and forum sites do not come from published human trials.

The first registered trial of MOTS-c in people is a phase 2 study that started in February 2026. Its public record says "fixed dose once daily for 12 weeks" by subcutaneous injection, but it does not state the amount, and it has no results yet. So any number of milligrams that you see online is a guess, not a tested dose.

This guide explains what the evidence shows, where MOTS-c stands with the FDA, and how unit math works for a vial, with hypothetical numbers only. It does not recommend a dose, a schedule, or a cycle. If you consider MOTS-c, talk with a clinician who knows your full medication list.

What MOTS-c is

MOTS-c is a peptide of 16 amino acids that is encoded in mitochondrial DNA. Researchers described it in 2015 in the journal Cell Metabolism. In that paper, MOTS-c acted on a pathway that activates AMPK, an energy sensor in cells. In mice, MOTS-c treatment prevented insulin resistance that came with age and with a high-fat diet, and it prevented diet-induced obesity.

These results are the source of most claims about weight, insulin sensitivity, and endurance. They are mouse and cell results. A dose that works in a mouse does not convert directly to a human dose, and the effects in people are not yet known.

The evidence in people so far

Here is what exists, as of November 20, 2026:

Study type What exists Dose information
FDA review FDA found no human exposure data for MOTS-c drug products None
Registered trial NCT07505745, phase 2, recruiting "Fixed dose once daily," amount not stated
Published human outcome trials None found None
Mouse and cell studies Several, starting in 2015 Not applicable to people

The trial NCT07505745 is sponsored by Hudson Biotech. It plans to enroll 120 adults with prediabetes and overweight or obesity. People get subcutaneous MOTS-c or placebo once daily for 12 weeks, with lifestyle counseling. The main measure is a change in insulin sensitivity from a glucose tolerance test, and the trial also counts side effects over 16 weeks. The trial started on February 2, 2026. Until it reports results, nobody knows whether MOTS-c helps people or what dose is safe.

An earlier company tested a related molecule called CB4211 in a small trial. That molecule is an analog, which means it is a different compound from native MOTS-c. Its results do not tell you about vials sold as MOTS-c.

MOTS-c regulatory status

MOTS-c has three separate status points:

  1. Not an approved drug. No FDA label exists, so no label dose exists.
  2. Compounding. The FDA lists MOTS-c among nominated substances that were withdrawn. It notes a possible risk of immune reactions for some routes, and problems in how the peptide and its impurities are characterized.
  3. Advisory vote. On July 23, 2026, an FDA advisory committee voted 7 to 5, with 2 abstentions, to recommend MOTS-c for the list of bulk substances that pharmacies may compound. AJMC reports that this vote is not binding, that the FDA must still decide, and that rulemaking with public comment comes before any change.

A vote to allow compounding is not an approval and is not a finding that a dose is safe. Vials sold as "research use only" are not made for people and do not have the controls of a pharmacy product. Our comparison of MOTS-c vs SS-31 vs NAD+ shows how the evidence for these mitochondrial compounds differs.

MOTS-c side effects: what is known

No study has published a list of MOTS-c side effects in people. The FDA page points to two concerns: possible immune reactions and uncertain product quality. Other risks come from the injection itself and from the source of the vial:

  • Redness, itching, or a lump at the injection site.
  • Infection from a contaminated vial or from poor technique.
  • A wrong amount from a mislabeled vial or a math error.
  • Unknown effects on blood sugar, which matter if you also take a GLP-1 medicine or insulin.

The trial above counts side effects as one of its main measures. Until that kind of data is published, "no side effects" claims on seller pages have no evidence behind them. For skin reactions, see peptide injection site reaction.

MOTS-c 10 mg vial units: the math with hypothetical numbers

People often ask how many units are in a 10 mg vial of MOTS-c. The answer depends on the volume of water added, and the "dose" in the math has to come from a prescriber, because no tested dose exists. The numbers below are hypothetical round numbers that show the method only. They are not doses.

  1. Concentration (mg per mL) = mg in the vial ÷ mL of water.
  2. Volume (mL) = amount ÷ concentration.
  3. Units on a U-100 syringe = volume in mL × 100.
  4. Doses per vial = mg in the vial ÷ amount per injection.
Vial (hypothetical) Water Concentration Math amount 1 mg Math amount 0.5 mg
10 mg 1 mL 10 mg/mL 0.10 mL, 10 units 0.05 mL, 5 units
10 mg 2 mL 5 mg/mL 0.20 mL, 20 units 0.10 mL, 10 units
10 mg 3 mL 3.33 mg/mL 0.30 mL, 30 units 0.15 mL, 15 units
10 mg 5 mL 2 mg/mL 0.50 mL, 50 units 0.25 mL, 25 units

Two errors cause most mistakes:

  • mg and mcg. 1 mg is 1,000 mcg. A number read in the wrong unit is wrong by a factor of 1,000.
  • Small volumes. At 10 mg/mL, a small amount is only a few units, and a small reading error is a large dose error. More water gives a larger, easier-to-read volume for the same amount.

Confirm every draw with your prescriber or pharmacist, in mL and in units, before you inject. The free peptide calculator shows the concentration, the units, and the doses per vial. See also how to reconstitute peptides with BAC water and how many doses are in a vial.

Logging a MOTS-c course in Vital

Online, MOTS-c is usually described in "courses" with a start and an end. Vital does not suggest a course length. It records the plan that you and your clinician set.

In Vital, you can attach a course to a saved peptide:

  • Set a start date, and an end by a duration in weeks, by a fixed date, or no end.
  • See a progress bar with the current week, and the days left near the end.
  • Turn on a reminder on day one and a warning before the course ends.
  • Pause a course, which stops its dose reminders without deleting the plan.

Each dose log can keep the vial mass and water volume, the injection site, the source type, the lot number, the expiration date, and any symptoms with a severity. The Vital peptide directory shows MOTS-c with its FDA status and a "Limited Data" evidence level, with links to the trial record and the FDA page. A complete log helps your clinician judge whether anything changed. For a paper version, see the peptide injection log template. For other schedule options, see custom peptide injection schedule.

Questions to ask before you consider MOTS-c

Use these questions with a clinician or pharmacist:

  1. Which human data support this use, and how large were the studies?
  2. Who made the vial, and is there a certificate of analysis from a third-party lab?
  3. Does the vial label give the mass in mg, the lot number, and the expiration date?
  4. How will MOTS-c interact with my other medicines, including a GLP-1 or insulin?
  5. Which tests will show whether it does anything for me?

For quality checks on a seller, see peptide catalog source checks. For combinations, see stacking peptides with a GLP-1.

When to get medical care

Get emergency care for swelling of the face, lips, tongue, or throat, hives with trouble breathing, or chest pain. Get medical care soon for any of these signs:

  • A hot, red, spreading, or very painful injection site, or pus.
  • Fever or chills after an injection.
  • Shakiness, sweating, or confusion, which can be signs of low blood sugar, mainly if you also take insulin or a GLP-1 medicine.
  • A racing or irregular heartbeat, or fainting.

If you think you injected too much, call your clinician or Poison Help at 1-800-222-1222.


Hudson Biotech is named only as the sponsor of a registered trial. Vital is independent and not affiliated with these companies.

Free toolPeptide reconstitution calculator

Things to watch

Practical flags drawn from prescribing information and clinical guidance. Vital surfaces these in the dose log to help you spot them early.

  • Online MOTS-c protocols

    No published human trial supports any MOTS-c dose. The FDA says it has not identified human exposure data on MOTS-c drug products.

  • Research use only vials

    These products are not made for people and do not have pharmacy quality controls. The FDA notes problems in how MOTS-c and its impurities are characterized.

  • Possible immune reactions

    The FDA compounding page lists a possible immunogenicity risk for some routes of MOTS-c.

  • mg and mcg mix-ups

    1 mg is 1,000 mcg. A number read in the wrong unit gives a draw that is wrong by a factor of 1,000.

  • Use with insulin or a GLP-1 medicine

    MOTS-c is studied for insulin sensitivity, and its effects on blood sugar in people are not known. Tell your prescriber about every product you inject.

Frequently asked questions

  • There is no recommended or approved MOTS-c dosage for people. MOTS-c is not an FDA-approved drug, and the FDA says it has not identified human exposure data on MOTS-c drug products. The first registered phase 2 trial has not reported results.

  • It depends on the water added. Math example with hypothetical numbers: 10 mg in 2 mL is 5 mg/mL, so 1 mg is 0.20 mL, or 20 units on a U-100 syringe. This is not a dose. Confirm any draw with your prescriber or pharmacist.

  • Yes. NCT07505745 is a phase 2 trial in 120 adults with prediabetes and overweight or obesity, with once-daily subcutaneous MOTS-c or placebo for 12 weeks. It started in February 2026, and its record does not state the dose amount.

  • No study has published a list of side effects in people. The FDA notes a possible risk of immune reactions and quality concerns. Injection site reactions, infection from a contaminated vial, and dose errors are also possible.

  • An FDA advisory committee voted 7 to 5 in July 2026 to recommend MOTS-c for the compounding bulks list. The vote is not binding, and the FDA must still decide and complete rulemaking. MOTS-c is not an approved drug.

  • Record the start date, the planned end, the vial mass and water volume, each injection site, the lot number, and any symptoms. In Vital, you can attach a course with an end date, reminders, and a pause option to a saved peptide.

Sources

  1. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks · U.S. Food and Drug Administration
  2. MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (NCT07505745) · ClinicalTrials.gov, U.S. National Library of Medicine
  3. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance · NIH / PubMed (Cell Metabolism, 2015)
  4. FDA Panel Backs 6 Peptides for Compounding · AJMC

This page summarizes publicly available information from the sources listed above and is for educational use only. It is not medical advice. Consult a qualified healthcare professional for personal dosing guidance.

Track every shot, every change

Vital logs every GLP-1 injection and peptide dose, then surfaces patterns your scale can't show. Free on iOS and Android.